Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Saudi Food and Drug Authority (SFDA) has granted approval for Organogenesis' treatment of diabetic foot ulcers and other chronic wounds, Apligraf.
Subscribe to our email newsletter
Apligraf is a living cell based product used by physicians to heal chronic wounds in patients in the US and around the world.
Apligraf contains two layers of human living cells: an outer protective layer of differentiated keratinocytes and an inner layer of fibroblasts in a collagen matrix.
The company said that in multiple controlled clinical studies, Apligraf has been shown to be an effective and safe wound care treatment, superior to conventional treatments.
Organogenesis claims that Apligraf was the first bioengineered cell based product to receive US Food and Drug Administration approval for chronic wounds.